Articles
Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors
William J. Bodell ; Donald D. Giannini ; Samuel Hassenbusch ; Victor A. Levin
read the full article in PDF format >
Stereotactic Injection of DTI-015 Into Recurrent Malignant Gliomas: Phase I/II Trial 9 - 16
Samuel J. Hassenbusch, Emilio M. Nardone, Victor A. Levin, Norman Leeds and Dennis Pietronigro
read the full article in PDF format >
Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015
William J. Bodell , Donald D. Giannini, Saira Singh, Dennis Pietronigro and Victor A. Levin
read the full article in PDF format >
DTI-015 Produces Cures in T9 Gliosarcoma 17 - 22
Dennis Pietronigro, Frank Drnovsky, Humberto Cravioto and Joseph Ransohoff
read the full article in PDF format >
Press Releases
01/24/2003
New anti-cancer drug (DTI-015) from Direct
Therapeutics shows safety and evidence of activity in treating advanced
brain cancer
10/15/2002
Direct Therapeutics Receives Approval to
Begin European Trial of New Brain Cancer Drug
09/25/2002
Direct Therapeutics Completes Enrollment
of Phase I/II Trial of New Brain Cancer Drug
04/23/2002
New Brain Cancer Drug Receives Orphan Drug
Designation in the European Union
07/20/2001
Direct Therapeutics Awarded Patent for
Medical Injection Device
New design allows doctors to more accurately administer drugs directly
to a disease site
06/11/2001
Direct Therapeutics Awarded SBIR Grant
12/14/2000
Direct Therapeutics Announces Completion
of Private Placement
10/3/2000
Direct Therapeutics Announces Two Phase
I/II Clinical Trials of DTI-015 in Brain Tumors
8/8/2000
Direct Therapeutics Announces Orphan Drug
Designation for DTI-015, a Novel Brain Tumor Therapy
|
